<p>Amylyx Pharmaceuticals（納斯達克代碼：AMLX - 獲取免費報告）於週四發佈了季度財報。公司報告每股收益（EPS）為（$0.37），低於市場共識預期的（$0.34），差距為（$0.03），FiscalAI 報道。</p>
<ul>
<li>3 家小型生物科技公司，2024 年有潛在突破</li>
</ul>
<p>以下是 Amylyx Pharmaceuticals 電話會議的關鍵要點：</p>
<ul>
<li><strong>Avexitide LUCIDITY</strong> 在 3 月底隨機分配並給最後一名參與者用藥，仍按計劃完成為期 16 周的試驗，預計在 2026 年第三季度公佈初步結果，同時 NDA 部分已在起草中，以支持 2027 年可能的批准和上市，如果結果積極。</li>
<li>公司啓動了一項美國擴展接入計劃，最多可容納 250 名成年人，並計劃在今夏啓動疾病狀態教育活動，並引用獨立的基於索賠的市場估計，約有 <strong>160,000</strong> 名美國人患有 PBH，內分泌科醫生在可用的批准療法出現時表現出強烈的治療意願。</li>
<li>Amylyx 報告現金和可交易證券為 2.798 億美元，並表示這筆資金將支持預計到 <strong>2028</strong> 年的現金流，涵蓋包括 LUCIDITY 結果公佈和潛在商業化活動在內的關鍵里程碑。</li>
<li>更廣泛的管道進展包括針對長效 GLP-1 拮抗劑 <strong>AMX0318</strong> 的 IND 啓用工作（目標為 2027 年 IND）、即將公佈的 Wolfram 綜合症 <strong>AMX0035</strong> 的第 96 週數據，以及預計在即將召開的科學會議上公佈的 <strong>AMX0114</strong> ALS 試驗第一組的生物標誌物數據。</li>
<li>第一季度運營費用上升至 4380 萬美元（同比增長 16%），主要由於對 avexitide 的研發支出增加，以及向 Gubra 支付的 400 萬美元里程碑款項，此外，由於該付款和年度獎金，公司本季度現金使用略有增加。</li>
</ul>
<p>獲取 <strong>Amylyx Pharmaceuticals</strong> 的提醒：</p>
<h2>Amylyx Pharmaceuticals 價格表現</h2>
<p>週四交易時段，AMLX 下跌 0.86 美元，達到 15.20 美元。共有 1,451,469 股股票交易，較其平均交易量 1,021,572 股有所增加。該公司的 50 日簡單移動平均為 15.36 美元，200 日簡單移動平均為 14.26 美元。公司市值為 16.9 億美元，市盈率為-9.81，貝塔值為-0.11。Amylyx Pharmaceuticals 的 52 周低點為 4.20 美元，52 周高點為 18.60 美元。</p>
<h2>分析師設定新目標價</h2>
<ul>
<li>這些生物科技公司針對多種神經退行性疾病</li>
</ul>
<p>幾位股票研究分析師最近對 AMLX 股票發佈了報告。美國銀行在 2 月 20 日的研究報告中將 Amylyx Pharmaceuticals 的目標價從 15.00 美元上調至 19.00 美元，並給予該股票 “買入” 評級。Wall Street Zen 在 3 月 7 日的研究報告中將 Amylyx Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。瑞穗證券在 4 月 28 日的研究報告中將 Amylyx Pharmaceuticals 的目標價從 19.00 美元上調至 21.00 美元，並給予該股票 “跑贏大盤” 評級。古根海姆在 3 月 19 日的研究報告中將 Amylyx Pharmaceuticals 的目標價從 25.00 美元上調至 30.00 美元，並給予該股票 “買入” 評級。最後，HC Wainwright 在 3 月 25 日的研究報告中重申了 “買入” 評級，並對 Amylyx Pharmaceuticals 的目標價設定為 34.00 美元。一位投資分析師給予該股票 “強烈買入” 評級，九位分析師給予 “買入” 評級，兩位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 23.00 美元。</p>
<p><strong>查看我們對 Amylyx Pharmaceuticals 的最新分析</strong></p>
<h2>機構投資者對 Amylyx Pharmaceuticals 的看法</h2>
<ul>
<li>Amylyx Pharmaceuticals 在成功推出藥物後實現盈利</li>
</ul>
<p>大型投資者最近增加或減少了對公司的持股。Meeder Asset Management Inc.在第四季度收購了價值 25,000 美元的 Amylyx Pharmaceuticals 新股份。加州教師退休系統在第二季度收購了價值 28,000 美元的 Amylyx Pharmaceuticals 新股份。Legal &amp; General Group Plc 在第二季度收購了價值 47,000 美元的 Amylyx Pharmaceuticals 新股份。法國巴黎銀行金融市場在第二季度將其在 Amylyx Pharmaceuticals 的持股增加了 433.2%。法國巴黎銀行金融市場目前擁有 7267 股該公司的股票，價值 47,000 美元，此前在上個季度又購買了 5904 股。最後，凱通國際資產管理有限公司在第四季度將其在 Amylyx Pharmaceuticals 的持股增加了 1,116.9%。凱通國際資產管理有限公司目前擁有 4454 股該公司的股票，價值 54,000 美元，此前在上個季度又購買了 4088 股。95.84% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Amylyx Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Amylyx Pharmaceuticals, Inc 是一家生物製藥公司，致力於開發針對罕見和嚴重神經疾病的治療方案。公司成立於 2013 年，總部位於馬薩諸塞州劍橋，專注於利用新穎的方法針對與神經退行性疾病相關的細胞通路。Amylyx 的研究平台以小分子療法為中心，旨在保護神經元並支持患有目前缺乏或沒有疾病修飾治療選項的患者的細胞健康。</p>
<p>公司的主要產品 AMX0035 在美國以 Relyvrio 的商標銷售。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Amylyx Pharmaceuticals</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1MWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1MWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Amylyx Pharmaceuticals 嗎？</h2>
<p>在考慮投資 Amylyx Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意之前購買的股票……而 Amylyx Pharmaceuticals 並不在名單上。</p>
<p>雖然 Amylyx Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AMLX

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

標普生物技術 3 倍做多 - Direxion

醫藥突破 ETF - ALPS

基因改革 ETF - ARK

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

<p>Amylyx Pharmaceuticals（納斯達克代碼：AMLX）報告的季度每股收益為（$0.37），低於預期$0.03。該公司擁有 2.798 億美元的現金，足以支持運營到 2028 年。主要進展包括 LUCIDITY 試驗和美國擴展接入計劃。分析師設定了新的價格目標，普遍評級為 “適度買入”，目標價為$23.00。機構投資者持有 95.84% 的股份，顯示出對該公司的強烈興趣</p>

<p>Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.03), FiscalAI reports.</p>
<div class="lb-trans"><p>Amylyx Pharmaceuticals（納斯達克代碼：AMLX - 獲取免費報告）於週四發佈了季度財報。公司報告每股收益（EPS）為（$0.37），低於市場共識預期的（$0.34），差距為（$0.03），FiscalAI 報道。</p>
</div><ul>
<li>3 small-cap biotechs with potential breakthroughs in 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家小型生物科技公司，2024 年有潛在突破</li>
</ul>
</div><p>Here are the key takeaways from Amylyx Pharmaceuticals' conference call:</p>
<div class="lb-trans"><p>以下是 Amylyx Pharmaceuticals 電話會議的關鍵要點：</p>
</div><ul>
<li><strong>Avexitide LUCIDITY</strong> randomized and dosed its last participant in late March and remains on track to complete the 16-week trial with a top-line readout expected in Q3 2026, while NDA sections are already being drafted to support a potential 2027 approval and launch if results are positive.</li>
<li>The company launched a U.S. expanded access program for up to 250 adults, is initiating a disease‑state education campaign this summer, and cites an independent claims-based market estimate of ~ <strong>160,000</strong> people in the U.S. with PBH, with endocrinologists showing high intent to treat if an approved therapy becomes available.</li>
<li>Amylyx reported $279.8 million in cash and marketable securities and says this capital funds an anticipated cash runway into <strong>2028</strong>, covering key milestones including the LUCIDITY readout and potential commercialization activities.</li>
<li>Broader pipeline progress includes IND‑enabling work for the long‑acting GLP‑1 antagonist <strong>AMX0318</strong> (targeting a 2027 IND), forthcoming week‑96 data for <strong>AMX0035</strong> in Wolfram syndrome, and biomarker data from cohort 1 of the <strong>AMX0114</strong> ALS trial expected at an upcoming scientific meeting.</li>
<li>Q1 operating expenses rose to $43.8 million (up 16% year‑over‑year) driven by higher R&amp;D spend on avexitide and a $4.0 million milestone payment to Gubra, and the company reported slightly higher cash usage this quarter due to that payment and annual bonuses.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Avexitide LUCIDITY</strong> 在 3 月底隨機分配並給最後一名參與者用藥，仍按計劃完成為期 16 周的試驗，預計在 2026 年第三季度公佈初步結果，同時 NDA 部分已在起草中，以支持 2027 年可能的批准和上市，如果結果積極。</li>
<li>公司啓動了一項美國擴展接入計劃，最多可容納 250 名成年人，並計劃在今夏啓動疾病狀態教育活動，並引用獨立的基於索賠的市場估計，約有 <strong>160,000</strong> 名美國人患有 PBH，內分泌科醫生在可用的批准療法出現時表現出強烈的治療意願。</li>
<li>Amylyx 報告現金和可交易證券為 2.798 億美元，並表示這筆資金將支持預計到 <strong>2028</strong> 年的現金流，涵蓋包括 LUCIDITY 結果公佈和潛在商業化活動在內的關鍵里程碑。</li>
<li>更廣泛的管道進展包括針對長效 GLP-1 拮抗劑 <strong>AMX0318</strong> 的 IND 啓用工作（目標為 2027 年 IND）、即將公佈的 Wolfram 綜合症 <strong>AMX0035</strong> 的第 96 週數據，以及預計在即將召開的科學會議上公佈的 <strong>AMX0114</strong> ALS 試驗第一組的生物標誌物數據。</li>
<li>第一季度運營費用上升至 4380 萬美元（同比增長 16%），主要由於對 avexitide 的研發支出增加，以及向 Gubra 支付的 400 萬美元里程碑款項，此外，由於該付款和年度獎金，公司本季度現金使用略有增加。</li>
</ul>
</div><p>Get <strong>Amylyx Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Amylyx Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Amylyx Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Amylyx Pharmaceuticals 價格表現</h2>
</div><p>AMLX traded down $0.86 during trading hours on Thursday, reaching $15.20. 1,451,469 shares of the stock traded hands, compared to its average volume of 1,021,572. The firm's fifty day simple moving average is $15.36 and its two-hundred day simple moving average is $14.26. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -9.81 and a beta of -0.11. Amylyx Pharmaceuticals has a fifty-two week low of $4.20 and a fifty-two week high of $18.60.</p>
<div class="lb-trans"><p>週四交易時段，AMLX 下跌 0.86 美元，達到 15.20 美元。共有 1,451,469 股股票交易，較其平均交易量 1,021,572 股有所增加。該公司的 50 日簡單移動平均為 15.36 美元，200 日簡單移動平均為 14.26 美元。公司市值為 16.9 億美元，市盈率為-9.81，貝塔值為-0.11。Amylyx Pharmaceuticals 的 52 周低點為 4.20 美元，52 周高點為 18.60 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><ul>
<li>These biotechs targeting multiple neurodegenerative diseases</li>
</ul>
<div class="lb-trans"><ul>
<li>這些生物科技公司針對多種神經退行性疾病</li>
</ul>
</div><p>Several equities research analysts have recently issued reports on AMLX shares. Bank of America increased their price objective on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, February 20th. Wall Street Zen raised shares of Amylyx Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, March 7th. Mizuho increased their price objective on shares of Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, April 28th. Guggenheim increased their price objective on shares of Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, March 19th. Finally, HC Wainwright reissued a &#34;buy&#34; rating and issued a $34.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $23.00.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對 AMLX 股票發佈了報告。美國銀行在 2 月 20 日的研究報告中將 Amylyx Pharmaceuticals 的目標價從 15.00 美元上調至 19.00 美元，並給予該股票 “買入” 評級。Wall Street Zen 在 3 月 7 日的研究報告中將 Amylyx Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。瑞穗證券在 4 月 28 日的研究報告中將 Amylyx Pharmaceuticals 的目標價從 19.00 美元上調至 21.00 美元，並給予該股票 “跑贏大盤” 評級。古根海姆在 3 月 19 日的研究報告中將 Amylyx Pharmaceuticals 的目標價從 25.00 美元上調至 30.00 美元，並給予該股票 “買入” 評級。最後，HC Wainwright 在 3 月 25 日的研究報告中重申了 “買入” 評級，並對 Amylyx Pharmaceuticals 的目標價設定為 34.00 美元。一位投資分析師給予該股票 “強烈買入” 評級，九位分析師給予 “買入” 評級，兩位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 23.00 美元。</p>
</div><p><strong>View Our Latest Analysis on Amylyx Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Amylyx Pharmaceuticals 的最新分析</strong></p>
</div><h2>Institutional Investors Weigh In On Amylyx Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Amylyx Pharmaceuticals 的看法</h2>
</div><ul>
<li>Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch</li>
</ul>
<div class="lb-trans"><ul>
<li>Amylyx Pharmaceuticals 在成功推出藥物後實現盈利</li>
</ul>
</div><p>Large investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. acquired a new stake in Amylyx Pharmaceuticals during the 4th quarter valued at $25,000. California State Teachers Retirement System acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at $28,000. Legal &amp; General Group Plc acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at $47,000. BNP Paribas Financial Markets grew its holdings in Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company's stock valued at $47,000 after purchasing an additional 5,904 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Amylyx Pharmaceuticals by 1,116.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,454 shares of the company's stock valued at $54,000 after purchasing an additional 4,088 shares in the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了對公司的持股。Meeder Asset Management Inc.在第四季度收購了價值 25,000 美元的 Amylyx Pharmaceuticals 新股份。加州教師退休系統在第二季度收購了價值 28,000 美元的 Amylyx Pharmaceuticals 新股份。Legal &amp; General Group Plc 在第二季度收購了價值 47,000 美元的 Amylyx Pharmaceuticals 新股份。法國巴黎銀行金融市場在第二季度將其在 Amylyx Pharmaceuticals 的持股增加了 433.2%。法國巴黎銀行金融市場目前擁有 7267 股該公司的股票，價值 47,000 美元，此前在上個季度又購買了 5904 股。最後，凱通國際資產管理有限公司在第四季度將其在 Amylyx Pharmaceuticals 的持股增加了 1,116.9%。凱通國際資產管理有限公司目前擁有 4454 股該公司的股票，價值 54,000 美元，此前在上個季度又購買了 4088 股。95.84% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Amylyx Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Amylyx Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.</p>
<div class="lb-trans"><p>Amylyx Pharmaceuticals, Inc 是一家生物製藥公司，致力於開發針對罕見和嚴重神經疾病的治療方案。公司成立於 2013 年，總部位於馬薩諸塞州劍橋，專注於利用新穎的方法針對與神經退行性疾病相關的細胞通路。Amylyx 的研究平台以小分子療法為中心，旨在保護神經元並支持患有目前缺乏或沒有疾病修飾治療選項的患者的細胞健康。</p>
</div><p>The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.</p>
<div class="lb-trans"><p>公司的主要產品 AMX0035 在美國以 Relyvrio 的商標銷售。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Amylyx Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Amylyx Pharmaceuticals</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1MWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=AMLX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Amylyx Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Amylyx Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Amylyx Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Amylyx Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛市場注意之前購買的股票……而 Amylyx Pharmaceuticals 並不在名單上。</p>
</div><p>While Amylyx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Amylyx Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Amylyx Pharmaceuticals (NASDAQ:AMLX) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Market Beat

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals（納斯達克股票代碼：AMLX）公佈季度財報，每股收益比預期低 0.03 美元